Sputnik V exports from Russia by country 2022

Russia was to export 250 million doses of the coronavirus (COVID-19) vaccine Sputnik V to India, which was among the major planned producers of the vaccine. In total, Indian companies planned to produce at least 1,152 million doses of Sputnik V per year. Furthermore, Mexico ordered a total of 24 million doses of the vaccine. Sputnik V was authorized in more than 70 countries worldwide as of January 2022. Russia applied for the vaccine approval in the European Union in January 2021, while several EU countries approved its use earlier, such as Hungary or Slovakia.

Russia's first vaccine against COVID-19

In August 2020, Russia registered Sputnik V, the world’s first approved vaccine against COVID-19, which was developed at Gamaleya Research Institute in Moscow. After the third phase of clinical trials, the vaccine's effectiveness was measured at 91.6 percent. The mass vaccination in Russia started in January 2021. In December 2020, 30 percent of Russians would get vaccinated against COVID-19 with Sputnik V.

Is Sputnik V available abroad?

In total, over 50 countries worldwide placed orders for Sputnik V from Russia. As of January 2021, The vaccine was used for vaccination in Russia, Belarus, Serbia. In October 2020, Russia applied for prequalification of Sputnik V at the WHO to speed up its availability worldwide. Other countries that would produce the vaccine, such as Brazil, China, India, or the Republic of Korea, would also sell it abroad. Among several countries surveyed in November 2020, the highest level of awareness about Sputnik V was recorded in Mexico.

Number of doses of the COVID-19 vaccine Sputnik V ordered from Russia or agreed to be produced abroad as of January 2022, by country (in millions)

Characteristic	Ordered from Russia	Planned domestic production
Algeria*	0.5	-
Argentina*	22	12 per year
Bahrain**	-	-
Belarus*	0.17	Up to 0.5 per month
Bolivia	5.2	-
Bosnia & Herzegovina	0.4	-
Brazil*	10	8 per month
China*	-	260 per year
Egypt*	25	40 per year
Guatemala	16	-
Honduras	0.07	-
Hungary	2	-
India*	250	1,152 per year
Iran**	60	-
Italy*	-	10 in 2,021
Kazakhstan*	6	7
Kyrgyzstan	0.02	-
Mexico**	24	-
Mongolia*	0.02	-
Montenegro	0.25	-
Nepal	25	-
North Macedonia	0.2	-
Palestine	100	-
Paraguay	1	-
Peru**	20	-
Philippines	10	-
San Marino	0.01	-
Serbia*	2	4
Slovakia	2	-
South Korea*	-	1,850 per year
Tunisia	0.5	-
Turkey**	50	-
Uzbekistan*	1	2
Venezuela**	10	-
Vietnam*	20	140

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

January 2022

More information

Region

Russia

Survey time period

As of January 2022

Supplementary notes

* Algeria: number of doses to be supplied in January 2021.
Argentina: production was to start in June at one million doses per month, with prospects to increase it to 4-5 million doses per month in the future.
Belarus: planned monthly production at Belmedpreparaty.
Brazil: planned production per month in the first half of 2021.
China: 60 million by Shenzhen Yuanxing Gene-tech, 100 million per year by TopRidge Pharma, and 100 million by Hualan Biological Bacterin Inc.
Egypt: by Minapharm and its German subsidiary ProBioGen AG, per year.
India: production of over 100 million doses per year by Hetero, up to 200 million per year by Virchow Biotech, 200 million by Stelis Biopharma, 252 million by Gland Pharma, 100 million per year by Panacea Biotec, and 300 million per year by Serum Institute of India (SII). The production is also planned by Morepen Laboratories.
Italy: production in 2021.
Kazakhstan: production by Karaganda Pharmaceutical Complex (KPC).
Mongolia: number of doses ordered as of March 2021; discussions on more deliveries were ongoing.
Serbia: planned production volume as of March 14, 2021.
South Korea: more than 150 million per year by GL Rapha, 500 million doses per year by a consortium including GL Rapha и ISU ABXIS, and 100 million per month by a consortium led by Huons Global Co Ltd.
Uzbekistan: production by Jurabek Laboratories.
Vietnam: expected annual production of 100 million doses by Vabiotech and 40 million by T&T Group.

** Plans to produce Sputnik V on its territory.
The statistic has been compiled from various local and international news sources, the Russian Direct Investment Fund, and national health ministries.

Figures have been rounded. Vaccine doses offered in humanitarian aid packages are not included.